Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company’s lead small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The study showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in Wilson’s disease.
Wilson’s disease is a genetic disorder characterized by copper accumulation in the liver and brain, leading to severe liver damage and neurological symptoms. Current treatments include chelation therapy and zinc acetate, but they often come with significant side effects and limited efficacy. The new findings suggest that Telomir-Zn may offer a novel approach by modulating intracellular metal homeostasis and redox balance.
The publication expands the scientific validation of Telomir-Zn as the company advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics that target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
For more information, the full press release is available at https://ibn.fm/fOSNo. The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO.
